(NASDAQ: VTVT) Vtv Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.74%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.18%.
Vtv Therapeutics's earnings in 2026 is $2,252,000.On average, 7 Wall Street analysts forecast VTVT's earnings for 2026 to be -$11,739,483, with the lowest VTVT earnings forecast at -$18,489,961, and the highest VTVT earnings forecast at -$4,259,915. On average, 7 Wall Street analysts forecast VTVT's earnings for 2027 to be -$17,669,883, with the lowest VTVT earnings forecast at -$30,147,515, and the highest VTVT earnings forecast at -$13,151,970.
In 2028, VTVT is forecast to generate -$17,215,728 in earnings, with the lowest earnings forecast at -$27,252,427 and the highest earnings forecast at -$12,407,519.